Pharmacologic therapies for malignant glioma: a guide for clinicians.
This review covers the medical options for malignant gliomas based on the results of recent clinical trials and updated information on molecular markers of prognostic and predictive value. In addition to alkylating agents, the antiangiogenic drug bevacizumab is increasingly used, particularly in cases of recurrence. Supportive care, including antiedema agents, antiepileptic drugs and anticoagulants, represent complementary treatment approaches of the utmost clinical importance.
Department of Neuro-Oncology, University of Turin, Via Cherasco 15, 10126, Turin, Italy, riccardo.soffietti@unito.it.
Riccardo
R
Soffietti
Luca
L
Bertero
Lorenzo
L
Pinessi
Roberta
R
Rudà
D001932:Brain Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy